Loading company
Genmab A/S
GMAB · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026 · before the open
$35.57+0.6%Sep 29 close
- 1M
- +7.0%
- 6M
- +37.7%
- 1Y
- +16.0%
- 5Y
- -17.3%
GMAB · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026 · before the open
$35.57+0.6%Sep 29 close
Genmab A/S is scheduled to report next on November 5, 2026, before the open. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending March 31, 2026, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2026 | 3 months toSep 30, 2024 | Change |
|---|---|---|---|
| Total Revenue | $896M | $816M | +9.80% |
| Profit | $53M | $186M | -71.51% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Genmab A/S has no earnings call transcript available.
“The second quarter of 2026 delivered clinical progress for our late-stage portfolio. Epcoritamab continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies, with strong data across multiple treatment settings and patient populations. At the same time, new data further support the development of Rina-S ® (rinatabart sesutecan) in combination in advanced ovarian cancer. Together, these results reflect our continued commitment to delivering meaningful advances for patients,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
The quote and the company description come from the 6-K Genmab A/S filed on August 6, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.